Back to Search
Start Over
A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX)
- Source :
- Journal of Clinical Oncology. 36:TPS7589-TPS7589
- Publication Year :
- 2018
- Publisher :
- American Society of Clinical Oncology (ASCO), 2018.
-
Abstract
- TPS7589Background: R-CHOP remains the standard of care in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL). However, pts with high-risk disease have poorer outcomes wi...
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
Standard of care
business.industry
Phases of clinical research
macromolecular substances
medicine.disease
Lymphoma
Polatuzumab vedotin
carbohydrates (lipids)
03 medical and health sciences
0302 clinical medicine
immune system diseases
hemic and lymphatic diseases
030220 oncology & carcinogenesis
Internal medicine
otorhinolaryngologic diseases
medicine
In patient
business
030215 immunology
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........17c35fda895317950616d62f87897b2c